ArticleFrontiers in oncology2026
Risk factors, severity-related factors, and clinical outcomes of immune checkpoint inhibitor-associated pneumonitis in elderly patients with lung cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the clinical characteristics, risk factors, severity-related factors, and clinical outcomes of immune checkpoint inhibitor-associated pneumonitis (CIP) after immune checkpoint inhibitor (ICI) treatment in elderly patients with lung cancer, providing evidence for risk identification and nursing management during ICI therapy. Methods: Clinical data from 206 elderly patients with lung cancer who received ICI therapy at the Second Affiliated Hospital of Naval Medical University between March 2024 and February 2026 were retrospectively collected. The incidence, onset time, and Common Terminology Criteria for Adverse Events (CTCAE) grade of CIP were recorded. Univariate and multivariable logistic regression analyses were performed to identify risk factors for CIP. Patients with CIP were classified into mild (grades 1-2) and moderate-to-severe (grade ≥3) groups. Clinical characteristics and outcomes were compared between the two groups. Firth penalized logistic regression was used to identify factors associated with CIP severity. Results: Among the 206 patients, 33 developed CIP (16.0%). The median time to CIP onset was 58 (45-82) days, and 81.8% of cases occurred within 90 days after ICI initiation. Twenty-two patients (66.7%) had mild CIP and 11 (33.3%) had moderate-to-severe CIP. Multivariable logistic regression identified prior thoracic radiotherapy (OR = 3.34, 95% CI: 1.45-7.69), pulmonary comorbidity (OR = 2.94, 95% CI: 1.30-6.63), and combination therapy (OR = 3.68, 95% CI: 1.36-10.00) as independent risk factors for CIP. Firth penalized logistic regression showed that pulmonary comorbidity (OR = 8.44, 95% CI: 1.42-95.17, P = 0.017) and prior thoracic radiotherapy (OR = 5.56, 95% CI: 1.07-39.63, P = 0.041) were associated with moderate-to-severe CIP. Conclusion: Most CIP cases occurred within the first 3 months after ICI treatment and were mild. Prior thoracic radiotherapy, pulmonary comorbidity, and combination therapy increased the risk of CIP, whereas pulmonary comorbidity and prior thoracic radiotherapy were associated with moderate-to-severe CIP in exploratory analysis. The above findings may provide a reference for the identification of patients with relevant risk factors, early monitoring, and nursing management during ICI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.